NCT02138162View on ClinicalTrials.gov

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Severe Hepatic ImpairmentNormal Hepatic Function
Interventions
DRUG

enzalutamide

oral

Trial Locations (1)

1612

Comac Medical Ltd., Sofia

Sponsors

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02138162 - A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men | Biotech Hunter | Biotech Hunter